Description

KENADION 10 MG INJ 1ML

Indications

KENADION 10 MG INJ 1ML, containing the active ingredient Phytonadione, is indicated for the prevention and treatment of vitamin K deficiency. It is primarily used in patients who are at risk of bleeding due to anticoagulant therapy, malabsorption syndromes, or liver disease. Additionally, it is indicated for the management of hemorrhagic disease of the newborn, a condition that can arise due to insufficient vitamin K levels in infants.

Mechanism of Action

Phytonadione, the active component of KENADION, is a fat-soluble vitamin that plays a crucial role in the synthesis of certain clotting factors in the liver. These factors include prothrombin (factor II), and factors VII, IX, and X, which are essential for the coagulation cascade. By facilitating the conversion of these factors into their active forms, KENADION helps restore the blood’s ability to clot, thereby reducing the risk of bleeding in patients with vitamin K deficiency.

Pharmacological Properties

KENADION is administered via intramuscular injection, allowing for rapid absorption and distribution throughout the body. The pharmacokinetics of Phytonadione indicate that it is primarily stored in the liver and adipose tissue. The half-life of the drug varies but is generally around 1 to 2 days. The metabolism of KENADION occurs in the liver, and it is excreted primarily in the bile and urine. The therapeutic effects of KENADION typically manifest within 6 to 12 hours following administration, making it an effective option for urgent management of bleeding disorders.

Contraindications

KENADION should not be used in patients who have a known hypersensitivity to Phytonadione or any of the excipients in the formulation. It is also contraindicated in individuals with certain conditions such as severe liver disease, where vitamin K metabolism may be impaired. Additionally, caution is advised in patients with a history of thrombosis or those receiving anticoagulant therapy, as inappropriate use may lead to thromboembolic events.

Side Effects

While KENADION is generally well-tolerated, some patients may experience side effects. Common adverse reactions include injection site reactions, such as pain, redness, or swelling. Rarely, systemic allergic reactions, including anaphylaxis, may occur. Other potential side effects include gastrointestinal disturbances, such as nausea or diarrhea. It is important for healthcare providers to monitor patients for any unusual symptoms following administration.

Dosage and Administration

The dosage of KENADION 10 MG INJ 1ML varies based on the indication and the severity of the vitamin K deficiency. For adults, the typical dose for the prevention of bleeding is 10 to 20 mg administered intramuscularly. In cases of hemorrhagic disease of the newborn, a single dose of 1 mg is often administered intramuscularly shortly after birth. The healthcare provider will determine the appropriate dosage and frequency based on the individual patient’s needs and clinical response.

Interactions

KENADION may interact with various medications, particularly anticoagulants such as warfarin. The administration of KENADION can counteract the effects of warfarin, leading to decreased anticoagulation and an increased risk of thrombosis. Therefore, it is essential to monitor the International Normalized Ratio (INR) closely in patients receiving both KENADION and anticoagulant therapy. Other drugs that may influence the pharmacokinetics of vitamin K include certain antibiotics, bile acid sequestrants, and anticonvulsants, which can affect vitamin K absorption and metabolism.

Precautions

Before administering KENADION, healthcare providers should conduct a thorough medical history and physical examination. Special caution should be exercised in patients with a history of liver disease, as their ability to metabolize the drug may be compromised. Additionally, patients with a history of thromboembolic events should be monitored closely. Pregnant and breastfeeding women should also consult their healthcare provider before use, as the safety of KENADION during pregnancy and lactation has not been fully established.

Clinical Studies

Several clinical studies have demonstrated the efficacy of KENADION in managing vitamin K deficiency and preventing bleeding complications. Research has shown that administration of Phytonadione significantly reduces the incidence of bleeding episodes in patients on anticoagulant therapy. In neonates, studies have confirmed that prophylactic administration of KENADION reduces the risk of hemorrhagic disease, thereby improving overall outcomes in this vulnerable population. These findings support the use of KENADION as a critical intervention in both adult and pediatric patients at risk of vitamin K deficiency.

Conclusion

KENADION 10 MG INJ 1ML is a vital therapeutic agent in the management of vitamin K deficiency and related bleeding disorders. Its mechanism of action, pharmacological properties, and clinical efficacy make it an essential tool in both acute and preventive care settings. However, healthcare providers must remain vigilant regarding contraindications, potential side effects, and drug interactions to ensure safe and effective use. As with any medication, patient education and monitoring are crucial to achieving optimal therapeutic outcomes.